Axolotl Biosciences
Develops and supplies fibrin-based bioinks for 3D bioprinting of human neural and cardiac tissues, enabling high cell viability for over a month to advance drug development and regenerative medicine.
- CEO / Founder
- Stephanie Willerth
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $265K
- Latest Round
- Grant
- Key Investors
- NGen; Genome Canada; Genome BC
Technology & Products
Key Products
TissuePrint-HV Kit (neurobioink); TissuePrint-LV Kit; TissuePrint Crosslinker; Consulting services
Technological Advantage
Proprietary fibrin-based bioink formulations optimized for extrusion bioprinters, achieving >80% cell viability post-printing vs. industry average ~60-70%, protected by patent-pending microsphere drug delivery system.
Differentiation
Value Proposition
Reduces time and cost for creating human tissue models by providing ready-to-use bioinks that maintain >80% cell viability post-printing, accelerating preclinical research and personalized medicine development.
How They Differentiate
3x higher cell viability retention (>80% vs. ~60-70% for competitors) for neural tissues over one month, with xeno-free, fibrin-based formulations tailored for hiPSC-derived cells, unlike generic collagen or alginate bioinks.
Market & Competition
Target Customers
Academic researchers, research institutions, pharmaceutical companies
Industry Verticals
Biotechnology; Pharmaceuticals; Academic Research
Competitors
CELLINK; BICO; Allevi
Growth & Milestones
Growth Metrics
Launched TissuePrint bioink globally in 2022; expanded consulting services in Q3 2022; selected as Canadian winner in Falling Walls Venture 2022.
Major Milestones
Founded in 2020; Launched TissuePrint bioink in 2022; Received $265K funding from NGen in 2022; Selected for Falling Walls Venture 2022; Partnership with StarFish Medical for production scaling
Notable Customers
StarFish Medical